Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia-Reference-Cited by-同舟云学术

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia

Published:2023-03 Issue: Volume:128 Page:355-363
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Ikeda Mahoko,Okugawa Shu^ORCID,Kashiwabara Kosuke,Moritoyo Takashi,Kanno Yoshiaki,Jubishi Daisuke,Hashimoto Hideki,Okamoto Koh^ORCID,Tsushima Kenji,Uchida Yasuki,Mitsumura Takahiro,Igari Hidetoshi,Tsutsumi Takeya,Araoka Hideki,Yatera Kazuhiro,Yamamoto Yoshihiro^ORCID,Nakamura Yuki,Otani Amato,Yamashita Marie,Wakimoto Yuji,Shinohara Takayuki^ORCID,Adachi-Katayama Maho^ORCID,Oyabu Tatsunori,Kanematsu Aoi,Harada Sohei,Takeshita Yuichiro^ORCID,Nakano Yasutaka^ORCID,Miyazaki Yasunari,Sakao Seiichiro,Saito Makoto^ORCID,Ogura Sho,Yamasaki Kei,Kawasuji Hitoshi^ORCID,Hataji Osamu,Inoue Jun-Ichiro,Seto Yasuyuki,Moriya Kyoji

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference28 articles.

1. Mechanisms of SARS-CoV-2 entry into cells;Jackson;Nat Rev Mol Cell Biol,2022

2. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses;Solidarity Trial Consortium;Lancet,2022

3. Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19;Cho;Transl Clin Pharmacol,2022

4. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020

5. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19;Hoffmann;Antimicrob Agents Chemother,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate;Journal of Intensive Medicine;2024-10

2. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate;Clinical Microbiology and Infection;2024-06

3. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis;Japanese Journal of Infectious Diseases;2024-05-31

4. Importance of sample size determination for randomized controlled clinical trials for coronavirus disease 2019 antiviral therapies;Pediatric Investigation;2024-01-24

5. Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system;Journal of Controlled Release;2023-12